Versant Capital Management
RPRX icon

Versant Capital Management’s Royalty Pharma RPRX Stock Holding History

Versant Capital Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$49.4K Buy
846
+112
+15% +$6.61K ﹤0.01% 1412
2026
Q2 		$41.2K Buy
734
+6
+0.8% +$312 ﹤0.01% 1501
2026
Q1 		$34.9K Sell
728
-22
-3% -$964 ﹤0.01% 1462
2025
Q4 		$29K Sell
750
-1,836
-71% -$70K ﹤0.01% 1405
2025
Q3 		$91.2K Buy
2,586
+2,058
+390% +$74.5K 0.01% 751
2025
Q2 		$19K Buy
528
+47
+10% +$1.56K ﹤0.01% 1563
2025
Q1 		$15K Buy
481
+361
+301% +$11.4K ﹤0.01% 1504
2024
Q4 		$3.06K Sell
120
-754
-86% -$20K ﹤0.01% 1949
2024
Q3 		$24.7K Sell
874
-189
-18% -$5.24K 0.01% 734
2024
Q2 		$28K Buy
1,063
+1,043
+5,215% +$28.9K 0.01% 587
2024
Q1 		$607 Hold
20
– – ﹤0.01% 1654
2023
Q4 		$562 Buy
20
+10
+100% +$275 ﹤0.01% 1653
2023
Q3 		$271 Buy
+10
New +$297 ﹤0.01% 1811

Other funds holding RPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $179B AUM 29.92% 1-Year Est. Return
Nordea Investment Management
Nordea Investment Management Stockholm, Sweden $127B AUM 33.25% 1-Year Est. Return
Amundi
Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Versant Capital Management's RPRX Position: Q3 2026 in Review

Versant Capital Management increased its Royalty Pharma (RPRX) stake by 15% in Q3 2026, buying an estimated $6.61K and bringing the position to 846 shares worth $49.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1412.

Versant Capital Management first reported a position in RPRX in Q3 2023 and has held it in 13 quarters since. The position peaked at $91.2K in Q3 2025. 393 funds tracked by Wall St. Rank hold RPRX as of Q3 2026.

  • Versant Capital Management held 846 shares of Royalty Pharma worth $49.4K as of Q3 2026.
  • Versant Capital Management bought 112 Royalty Pharma shares in Q3 2026, an estimated $6.61K.
  • Royalty Pharma made up ﹤0.01% of Versant Capital Management's portfolio in Q3 2026, its #1412 holding.
  • Versant Capital Management first reported a position in Royalty Pharma in Q3 2023 and has held it in 13 quarters since.
  • Versant Capital Management's Royalty Pharma position peaked at $91.2K in Q3 2025.
  • 393 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2026.

Based on Versant Capital Management's 13F filing for Q3 2026, filed 2 Oct 2026.